

## ΜΕΜΟ

**TO:**Drazen Ostovic

**CC:**Trish Hurter **Ivan Santos** 

FROM:Leigh Shultz **CONTIBUTORS:**Tom Gandek Chris Lindemann Kiki Luna Kari Lynn Dina Zhang

**SUBJECT:**Pharmaceutical Evaluation of L-224715

DATE:09 Apr 2002

L-224715 is a DP-IV inhibitor for the treatment of type II Diabetes Mellitus. The phosphate salt form has been chosen for development. The following report, written for inclusion in the SARC Technical Review Package, describes the chemical and physical properties of L-224715 phosphate known to date.

U:\L224715\Pharm Eval SARC Tech Rev L-224715.doc

Δ



DOCKET LARM Find authenticated court documents without watermarks at docketalarm.com.

### 1. Summary

L-224715 is a DP-IV inhibitor for the treatment of Type II Diabetes Mellitus. It is being developed as the crystalline phosphate salt, which exists as a single anhydrous polymorph to date. The phosphate salt is chemically stable in the bulk for 4 weeks under all conditions studied and is most stable in solution between pH 2-4. It consists of flake-like particles, with the mean particle size of the A-sheet delivery lot around 100  $\mu$ m. The material is cohesive and has good overall flow properties.

L-224715 was dosed to both rats and dogs in solution and exhibited linear pharmacokinetics with no adverse effects noted. The Phase I formulation will be neat drug dry-filled into HPMC capsules using the Xcelodose 600<sup>™</sup>, which was able to fill 0.1 mg (free base equivalents) of drug into a capsule in trials run by PR&D. HPMC capsules containing L-224715 phosphate show acceptable dissolution profiles both initially and after 4 weeks of storage at 40 °C/75% RH; 20-mg potency HPMC capsules dosed orally to dogs show similar exposures to the 2 mg/kg solution dose.

### 2. Description

L-224715 is a DP-IV inhibitor for the treatment of Type II Diabetes Mellitus. It has an improved in vitro profile over the Probiodrug compound P32/98 (L-000826), previously in development, and its backup, L-221869.

L-224715 is a  $\beta$ -amino acid derivative with a molecular weight of 407.321 g/mol and a molecular formula of C<sub>16</sub>H<sub>16</sub>F<sub>6</sub>N<sub>5</sub>O. It is being developed as the monobasic phosphate salt (L-224715-006F), molecular weight 505.317 g/mol (salt factor 0.806). The structure of the phosphate salt is shown in the figure below.




Figure 1. Structure of L-224715-006F (monobasic phosphate salt)

The phosphate salt is a white crystalline powder consisting of flake-like particles; this morphology affords good flow properties.

### 3. Test Substances

Chemical stability data were obtained using lot 70316-25 (bulk, gelatin mixtures, HPMC mixtures). Physical characterization data is primarily from the A-sheet delivery lot L-224715-006F006 (72471-11).

U:\L224715\Pharm Eval SARC Tech Rev L-224715.doc



Solubility data (exceptions noted in text) were generated with lot 70316-25. Physical stability data and Biopharmaceutical data were generated from lot 70316-35. Mechanical properties were determined using lot 70316-31.

### 4. Physical Characterization

### Microscopy

Samples of L-224715 phosphate salt were examined by optical microscopy and SEM and were found to consist of flake-like particles with some agglomeration. A representative SEM image (L-224715-006F006, A-sheet delivery lot) is shown in Figure 4.1 below.




Figure 4.1. SEM image of L-224715-006F006 (210X magnification)

### **Particle Size Distribution**

The PSD of several lots of L-224715 phosphate salt were determined in Physical Measurements on the Microtrac SRA150 (Table 4.1). Samples were sonicated for 30 seconds in Isopar G prior to measurement.

Table 4.1. Particle size of L-224715-006F			
Lot	Mean (µm)	95%<(μm)	%<5 μm
70316-077 (006F003)	38.4	90.0	1.5
70316-079 (006F004)	35.1	75.8	0.1
72471-011 (006F006)	92.3	212.4	5.6

The mean particle size of the flakes increased in the A-sheet delivery lot (006F006) with respect to earlier lots. The particle size distributions are illustrated graphically in Figure 4.2 below.

U:\L224715\Pharm Eval SARC Tech Rev L-224715.doc

DOCKE



Find authenticated court documents without watermarks at <u>docketalarm.com</u>.





Figure 4.2. Particle size distributions for lots of L-224715-006F

### **Thermal Properties**

Samples of L-224715-006F were analyzed by DSC and TGA to determine the melting point and residual solvent level of the salt. Representative DSC and TGA traces are shown below (Figure 4.3).



U:\L224715\Pharm Eval SARC Tech Rev L-224715.doc

R

Δ

Δ



DOCKE Μ Find authenticated court documents without watermarks at docketalarm.com.




Figure 4.3. DSC (top) and TGA (bottom) traces for L-224715-006F006

DSC data were collected in an open pan with heating at 10 °C/min under nitrogen. The melting point of the salt is 218.6 °C. The melt endotherm cannot be quantitated due to immediate decomposition of the solid upon melting. TG analysis shows 0.056% weight loss between 50 °C and the onset of melting, indicating little solvent remaining on the solid.

#### **X-ray Powder Diffraction**

XRPD analysis of the phosphate salt of L-224715 shows several strong reflections between 2-40  $^{\circ}2\theta$ , indicating this high crystallinity of the salt. No amorphous halo has been noted in any sample to date. The XRPD pattern for the A-sheet delivery lot is shown in Figure 4.4 below and is representative of the data obtained from samples of L-224715 phosphate salt from Process Research.

U:\L224715\Pharm Eval SARC Tech Rev L-224715.doc

DOCKF



Find authenticated court documents without watermarks at docketalarm.com.

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.